Detalhe da pesquisa
1.
Genomics to select treatment for patients with metastatic breast cancer.
Nature
; 610(7931): 343-348, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071165
2.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914339
3.
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Int J Cancer
; 152(5): 921-931, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36161271
4.
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
Ann Surg
; 277(1): e153-e161, 2023 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33534229
5.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 23(11): 1367-1377, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36183733
6.
Checkpoint inhibitors in a marriage: consented or arranged?
Br J Cancer
; 126(12): 1834-1836, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35523880
7.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 191(1): 191-207, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34687411
8.
Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression.
Mol Cancer
; 20(1): 136, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670568
9.
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).
Angiogenesis
; 23(2): 193-202, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31773439
10.
Optimizing drug development in oncology by clinical trial simulation: Why and how?
Brief Bioinform
; 19(6): 1203-1217, 2018 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28575140
11.
DPD status and fluoropyrimidines-based treatment: high activity matters too.
BMC Cancer
; 20(1): 436, 2020 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32423482
12.
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Int J Cancer
; 145(12): 3359-3369, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31087564
13.
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
Br J Cancer
; 121(12): 991-1000, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31719684
14.
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Breast Cancer Res Treat
; 173(2): 397-406, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30357526
15.
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.
Ann Surg Oncol
; 26(2): 356-365, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30539492
16.
The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
Br J Cancer
; 118(9): 1179-1188, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29563634
17.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
N Engl J Med
; 372(8): 724-34, 2015 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25693012
18.
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
J Neurooncol
; 138(2): 369-382, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29488184
19.
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Lancet Oncol
; 18(6): 743-754, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28526538
20.
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Lancet Oncol
; 18(4): 473-485, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28283282